Biotech News
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
investor.arbutusbio.com2026-05-06 15:28 EST
Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including